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I. Introduction/Literature Review 
According to the National Cancer Institute, breast cancer is the most commonly 
occurring cancer in the United States. The estimated number of new cases of breast 
cancer in 2019 was 268,600 with approximately 41,760 deaths.1  Although breast cancer 
accounts for ~15.2% of all cancers, only 6.9% of cancer deaths are due to breast cancer.1  
This low percentage of deaths relative to the number of cases is reflected in the five-year 
survival rate from 2009-2015 of 89.9%.1 Although the survival percentage is high, it 
varies with factors such as race/ethnicity and type of breast cancer.  
 
Breast Cancer 
Most breast cancers occur within the ducts of the breast. These ducts, which are 
composed of epithelial cells, form the channels through which milk made within the 
mammary gland travels to the nipple. Breast cancer can also occur within the lobes of the 
gland. These two types of cancer are referred to as ductal or lobular carcinomas, 
respectively2, and this represents one way in which breast cancer can be classified. Breast 
cancer can also be classified into one of five molecular subtypes.3 The subtypes are based 
on the presence or absence of estrogen and/or progesterone receptors and the expression 
of Her2 (human epidermal growth factor receptor 2) (Table 1). Each receptor is key to 
normal cellular proliferation and therefore, can serve as therapeutic targets for the 
treatment of breast cancer.4 Luminal A and B subtypes are similar, but are distinguished 
based on the levels of Ki67, which helps regulate the rate of cellular proliferation. 
Luminal A cancers express low levels, whereas luminal B cancers express high levels of 
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Ki67. The work in this thesis focuses on triple negative breast cancer (TNBC) cells,3 
which lack estrogen and progesterone receptors, and Her2.  
 
Subtype ER PR HER2 Ki67 
Luminal A + + - + 
Luminal B + + -/+ ++ 
TNBC - - - - 
HER2 
enriched - - + - 
Normal-like + + - - 
 
Table 1: Receptor Expression in Breast Cancer Subtypes Expression of estrogen 
receptor (ER), progesterone receptor (PR), and HER2 in each of the five different 
molecular subtypes of breast cancer.3 (TNBC, triple negative breast cancer) 
 
Triple Negative Breast Cancer  
Of the five types of breast cancer, triple negative breast cancer is the most 
aggressive. It accounts for 10% of all breast cancer diagnoses and has a 5-year survival 
rate of 76.5%.5 In contrast, other subtypes have survival rates of 83.4-94%.5 Treatment 
options for TNBC are fewer than those for other subtypes. With the expression of ER, 
receptor antagonists can be used, and drugs such as Herceptin® and lapatinib are available 
to treat HER-2-positive cancers.6 These targeted therapies are not options for the 
treatment of TNBC.   
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Nuclear-Cytoplasmic Shuttling 
The movement of certain proteins between the nucleus and cytoplasm of cells 
allows their function to be localization dependent.7 Proteins less than 40 kDa can freely 
diffuse through nuclear pores. Those with a molecular weight greater than 40 kDa are 
shuttled in and out of the nucleus by specific carrier proteins, or karyopherins. Importins 
are a type of karyopherin involved in the movement of protein and RNA from the 
cytoplasm to the nucleus. These transporters recognize specific sequences within the 
proteins termed nuclear localization sequences (NLS) that allow interaction and 
translocation at the expense of Ran-GTP. Karyopherins involved in nuclear export of 
proteins are referred to as exportins. There are many exportin proteins, but exportin 1 
(XPO1, also known as chromosome region maintenance 1 or CRM1) binds to a leucine 
rich nuclear export sequence (NES) within target proteins to move them out of the 
nucleus and into the cytoplasm. This, too, requires energy generated by GTP hydrolysis 
(Figure 1). 7 
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Figure 1: Nuclear-cytoplasmic shuttling Before nuclear export can 
occur, a complex of the exportin, cargo protein, and a Ran-GTP molecule 
must be formed. Once the complex is exported to the cytosol, Ran-GTP is 
hydrolyzed. This hydrolyzation provides energy for the exportin, cargo 
protein, and Ran-GTP complex to dissociate from one another. The 
exported protein remains in the cytosol and the exportin re-enters the 
nucleus.  
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The relevance of protein nuclear export to cancer is tied to the observations that a 
number of proteins, including some that regulate the cell cycle, undergo nuclear import 
and export as a means to regulate their function.8 Inhibition of nuclear export can result in 
dysregulation of the cell cycle. For example, inhibition of nuclear export of cyclin D1, a 
protein vital to cell cycle progression, results in tumor growth in immune compromised 
mice.9 p53 is a protein that is activated in the nucleus when there is DNA damage or a 
signal indicating the presence of oncogenic properties.7 Activated p53 stimulates 
apoptosis and is exported once it has done its job. This export, and the export of many 
other tumor suppressors, is carried out by XPO1, and many cancer cells overexpress 
XPO1. In a non-cancerous cell, tumor suppressors are well-regulated by XPO1 to prevent 
them from being activated in the nucleus when it is not necessary. When XPO1 is 
overexpressed, it is constantly shuttling tumor suppressors out of the nucleus. This 
promotes tumor formation and growth and can prevent apoptosis from occurring.7 The 
ability to inhibit XPO1 activity could return the level of regulation in cancerous cells to 
normal levels.  
 
Selinexor, A Nuclear Export Inhibitor 
Since XPO1 is upregulated in several types of cancer, it has become an attractive 
therapeutic target, as pharmacological inhibition of nuclear export could serve to treat 
patients. This concept has been proven effective in treating multiple myeloma, a cancer 
of the bone marrow. Selinexor, a nuclear export inhibitor, received FDA approval for the 
treatment of this cancer in 2019.10  
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Selinexor is a first in class SINE (selective inhibitor of nuclear export) drug that 
has been shown to induce apoptosis in triple negative breast cancer cells in vitro.11 
Specifically, selinexor inhibits XPO1 by blocking its binding site for protein transport. 
Studies indicate that selinexor treatment resulted in increased XPO1 mRNA expression, 
suggesting that the cells were trying to compensate for reduced nuclear export by 
synthesizing more XPO1.1 
The successful outcomes from clinical trials resulted in an expedited approval 
process for selinexor. Currently there are 21 ongoing clinical trials and nine trials have 
been completed using the drug. For acute myeloid leukemia (AML), diffuse large B cell 
lymphoma (DLBCL), multiple myeloma (MM), and soft tissue sarcoma, selinexor has 
been given an orphan drug status  in the United States. This means that a single 
company has the rights to try to develop a cure for a certain disease while receiving 
benefits such as tax reductions for certain clinical testing. In patients with breast cancer, 
selinexor has been shown to have anticancer effects when combined with 
chemotherapy.10 
Selinexor is not the first nuclear export inhibitor designed. Leptomycin B was 
first used in clinical trials in 1996.12 However, it was found to be too toxic to be used 
therapeutically. Karyopharm Therapeutics has developed a series of compounds that are 
structurally similar to leptomycin B. These compounds, designated with the prefix KPT, 
were shown to inhibit nuclear export, with KPT-330 being the most efficacious. KPT-330 
is selinexor.10   
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PI3K/Akt 
The PI3K/Akt pathway is frequently dysregulated in cancers and can contribute to 
disease progression.13 Akt is a cell survival kinase. It has the ability to phosphorylate a 
number of proteins to result in inhibition of apoptosis and changes in cell cycle 
progression.  Under normal conditions, Akt is activated when a growth factor binds to its 
receptor, which has tyrosine kinase activity associated with it. Through adapter proteins, 
phosphatidylinositol 3-kinase (PI3K) is activated and phosphorylates 
phosphatidylinositol 4,5-biphosphate (PIP2) to produce phosphatidylinositol 3,4,5-
triphosphate (PIP3) on the plasma membrane. PIP3 recruits proteins that contain a 
pleckstrin homology (PH) domain to the plasma membrane. This includes Akt and 
pyruvate dehydrogenase lipoamide kinase isozyme 1 (PDK1). PDK1 and Akt associate at 
PIP3 on the membrane, and Akt is phosphorylated by PDK1 at threonine 308 (T308), 
which partially activates Akt. Akt is further activated by phosphorylation by mTORC2 
(mammalian target of rapamycin complex 2) at serine 473 (S473). Activated Akt 
promotes cell growth, survival, and proliferation13 (Figure 2). 
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Figure 2: Akt activation pathway Activation of PIP3 occurs when 
growth factor binds to its tyrosine kinase receptor, initiating a cascade that 
leads to the activation of Akt.  
 
Akt function is regulated by phosphatase and tensin homolog (PTEN), which 
regulates PIP3 by dephosphorylating it and returning it to PIP2. Loss of PTEN function 
results in an increase in PIP3 and a constitutively activated Akt pathway. In addition, 
studies have shown that when PTEN function is lost, breast cancer cells are more 
sensitive to PI3K inhibitors.13 
Akt function is also dependent upon the subcellular localization of the protein. 
Akt translocates to the nucleus after being phosphorylated at the plasma membrane.14 
Although the mechanism of Akt nuclear import is not fully understood15, Akt contains a 
leucine-rich, leptomycin B sensitive, nuclear export sequence suggestive of nuclear 
export occurring via XPO1.14 
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While Akt s normal function aids in cellular survival, under certain conditions, 
these functions can trigger apoptosis via reactive oxygen species (ROS) production. This 
Akt-mediated increase in ROS has been demonstrated in glioblastoma and ovarian cancer 
cell lines.16 These studies showed that the increase in ROS triggered cell death via 
apoptosis.  
 
Reactive Oxygen Species 
Reactive oxygen species are oxygen radicals, such as hydroxyl radicals or 
hydrogen peroxide (OH, H2O2), produced by normal cellular reactions. They are 
important in many essential processes, such as immune defense mechanisms, but they can 
also be volatile and toxic.17 While ROS are necessary, when their levels in the cell 
become too high, oxidative stress occurs. This means that DNA, RNA, proteins, and 
lipids, all essential molecules for cellular survival, can be damaged, which has 
implications in overall health.19 ROS have both tumor suppressing and activating 
properties, which some chemotherapies utilize to create toxicity to kill cancer cells.18  
The PI3K/Akt pathway is frequently hyperactivated in cancer and this can result 
in an increase in cellular ROS levels. This occurs via an increase in normal metabolic 
processes that are activated by Akt and normally result in acceptable levels of ROS 
production. However, many cancer cells already have higher level of ROS in comparison 
to normal cells. Therefore, when more ROS are produced, the levels can become toxic 
and trigger apoptosis.16 
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Statement of Research Problem 
 Shuttling of proteins between the nucleus and cytoplasm can be an important 
regulatory process in the development of cancer and therefore a key therapeutic target. 
The nuclear export inhibitor selinexor, marketed as XPOVIO®, has been demonstrated to 
be effective in the treatment of certain cancers. However, the full mechanism by which 
this occurs is not known and very little is understood about its effects on triple negative 
breast cancer. The working hypothesis of this thesis states that selinexor inhibits the 
nuclear export of Akt, resulting in increased reactive oxygen species (ROS) and cell 
death of TNBC cell lines.  
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II. Materials and Methods 
BT-549 Cells 
The primary focus of this research was to investigate the effects of selinexor in 
triple negative breast cancer cells. Several triple negative breast cancer cell lines are 
available for research purposes. For this project, BT-549 cells were used. BT-549 cells 
are triple negative cells derived from a 72-year-old Caucasian female diagnosed with 
ductal carcinoma.20 The cells have a homozygous deletion for PTEN, an inhibitor of the 
PI3K/Akt pathway. Therefore, Akt should be constitutively active in these cells.  
 
Cell Culture 
BT-549 cells were purchased from American Type Culture Collection.  They 
were maintained in Roswell Park Memorial Institute (RPMI) medium supplemented with 
10% fetal bovine serum and 1% antibiotic-antimycotic solution. Cells were grown in a 
humidified incubator at 37°C in 5% carbon dioxide. 
 
Akt Activity Assays 
Activity assays were performed using kits from Cell Signaling Technology or 
Abcam. Cells were plated at a concentration of 5 x 106 cells in six 100 mm dishes. 
Approximately 20 hours post plating, three plates were treated with 1 µM selinexor 
(Selleck Chemical) and three were treated with corresponding volumes of dimethyl 
sulfoxide (DMSO), the vehicle for selinexor, to serve as the negative control. The cells 
were harvested 21 hours later by first rinsing them in cold phosphate-buffered saline 
(PBS) followed by incubation in 0.5 mL cold Cell Lysis Buffer for 5 minutes. Cells were 
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scraped off plates and transferred to microcentrifuge tubes to be sonicated on ice. The 
cells were microcentrifuged for 10 minutes at 4ºC at 14,000 x g and the supernatant was 
removed. This cell lysate, containing proteins, was stored at -80ºC, to be later used for 
protein analysis.  
The protein concentration for each sample was determined by BioRad Protein 
Assay Dye Reagent Concentrate. Akt was immunoprecipitated from 200 µg of protein by 
incubating overnight at 4ºC with immobilized phospho-Akt primary antibody conjugated 
to beads. The immunoprecipitated Akt was isolated and incubated with glycogen 
synthase kinase-3 (GSK-3) protein, for 30 minutes at 30ºC. GSK-3 is a known substrate 
of Akt and its phosphorylation by the immunoprecipitated Akt indicates activation of the 
kinase. The samples were then subjected to SDS-PAGE gel electrophoresis, and the 
proteins were transferred to a membrane using the Trans-Blot Turbo Transfer System 
(Bio-Rad). After blocking the membrane in blocking buffer (tris-buffered saline [TBST] 
with 5% nonfat dried milk), it was incubated in a phospho-GSK 3 (Ser473) rabbit 
monoclonal antibody at a 1:1000 dilution in 10mL blocking buffer overnight at 4ºC. The 
following day, the membrane was rinsed three times for 10 minutes each before being 
incubated with a horseradish peroxidase (HRP) conjugated donkey anti-rabbit IgG 
secondary antibody (Jackson ImmunoResearch) at a 1:10,000 dilution in blocking buffer. 
The membrane was rinsed again three times for ten minutes each and developed using the 
SuperSignal West Pico PLUS Chemiluminescent Substrate Kit from Thermo Scientific.  
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Western Blots 
Cells were plated at a concentration of 5 x 106 cells in six 100 mm dishes. 
Approximately 20 hours post plating, three plates were treated with 1 µM selinexor and 
three were treated with DMSO, as a control. The cells were harvested 21 hours later by 
first rinsing them in cold phosphate-buffered saline (PBS) followed by scraping in 1 mL 
cold PBS per plate. The cells were collected into 15 mL conical tubes. The cells were 
centrifuged at 500xg for 5 minutes at 4ºC, and the supernatant was decanted. Depending 
on the size of the pellet, 35 µL- 50 µL of RIPA with Halt Phosphatase Inhibitor (Thermo 
Scientific) and Protease Inhibitor Cocktail (Sigma) (final dilution of 1:100) was added 
and the pellet resuspended before being transferred to a 1.5 mL microcentrifuge tube. The 
tubes were vortexed for ~10 seconds before being placed on ice for 30 minutes. After the 
30-minute period, DNA was sheared by using a 1mL syringe and a 24-gauge needle 
before being centrifuged at 18,000 x g at 4ºC for 15 minutes. A protein assay using 
BioRad Protein Assay Dye Reagent Concentrate was performed on the supernatant (cell 
lysate) to determine protein concentration.  
Western blots were performed to detect proteins by subjecting cell lysates to SDS-
PAGE gel electrophoresis, and the proteins were transferred to a membrane using the 
Trans-Blot Turbo Transfer System (Bio-Rad). After blocking the membrane in blocking 
buffer (tris-buffered saline [TBST] with 5% nonfat dried milk), it was incubated in a 
primary antibody at a 1:1000 dilution in 10mL blocking buffer overnight at 4ºC. The 
following day, it was washed three times for ten minutes each time before being 
incubated with a secondary antibody at a 1:10,000 dilution in blocking buffer. The 
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membrane was washed again and developed using the SuperSignal West Pico PLUS 
Chemiluminescent Substrate Kit from Thermo Scientific. 
In order to ensure changes in Akt activity were not due to differences in Akt 
protein levels, a total Akt Western blot was performed on both the vehicle (DMSO) and 
selinexor-treated cell lysates. To probe for Akt, a pan antibody for Akt was used to 
incubate the membrane. Western blots were also performed to analyze changes in the 
levels of phosphorylated Akt as a second way of demonstrating Akt activity. This was 
performed using a phospho (Thr308)-Akt rabbit polyclonal antibody to specifically 
analyze Akt phosphorylation at threonine 308. 
To ensure equal loading of the samples, the membranes from the total Akt and 
phospho-Akt Westerns were stripped and reprobed for actin. The membranes were rewet 
in methanol using the capillary technique. To strip the primary antibody from the 
membrane, the membrane was washed six times in deionized water by shaking for 30 
seconds each time before being incubated at room temperature in 0.1M HCl for 5 minutes 
with shaking. Next, the membrane was incubated in blocking buffer on the shaker at 
room temperature for 1 hour before being rinsed in 1x TBST. For actin reprobing of total 
Akt Westerns, 3% BSA blocking buffer (0.3g bovine serum albumin, 10 mL 1x TBST) 
was used, while for actin reprobing of phospho-Akt Westerns, 5% milk blocking buffer 
(TBST with 5% dried milk) was used.  The membrane was then incubated on the shaker 
at room temperature for 30 minutes in a 1:1500 dilution of a monoclonal antibody against 
ß-actin. The membranes were washed three times for 10 minutes each time before being 
incubated for 45 minutes in the secondary antibody (peroxidase conjugated donkey anti-
mouse IgG) at a 1:15,000 dilution in blocking buffer. After washing again, membranes 
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were developed using the SuperSignal West Pico PLUS Chemiluminescent Substrate Kit 
from Thermo Scientific. Equal signals between lanes demonstrated equal loading 
between samples. 
 
Indirect Immunofluorescence 
To determine if selinexor caused nuclear accumulation of Akt, indirect 
immunofluorescence was performed. BT-549 cells were plated at 750,000 cells per plate 
on 35 mm MatTek dishes. After approximately 48 hours, cells were treated with 1 µM 
selinexor or equal volume DMSO and harvested 21 hours later. Cells were washed in 1 
mL filtered PBS and fixed in 2% paraformaldehyde. Cells were washed twice for five 
minutes each in 1 mL 0.1M cold tris-glycine buffer. Cells were again washed with 
filtered PBS for five minutes. Following incubation in blocking buffer (5% normal 
donkey serum, 1% BSA, 0.1% Triton-X 100 in PBS) for 30 minutes, the primary Akt 
(pan) antibody at a 1:400 dilution in blocking buffer was added. Plates were incubated 
overnight at 4ºC in a moistened environment. The next day, the plates were washed three 
times in filtered PBS for 5 minutes each. Cells were then incubated in a C 3 donkey 
anti-rabbit IgG diluted at 1:1500 in blocking buffer in the dark at room temperature for 
45 minutes. The cells were washed in filtered PBS three times for five minutes each. 
Cells were then incubated in 4 ,6-diamidino-2-phenylindole (DAPI) at a 1:1500 dilution 
in filtered PBS for two minutes. The cells were washed again in filtered PBS and then 
rinsed in DI water before Aqua Poly Mount was added to the plate. Cells were viewed 
under a Nikon Eclipse TI-5 fluorescence microscope. Cy3 was excited at 550 nm and 
DAPI at 358 nm. Cells were imaged with NIS Elements BR4.6 imaging software.  
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ROS Assays 
To determine whether ROS were increased in response to selinexor, ROS assays 
were performed. BT-549 cells were analyzed using the Cellular ROS Assay Kit (Red) 
from Abcam. This procedure consisted of several steps. First, BT-549 cells were plated at 
specified concentrations. The cells were then treated with 100 µL ROS Red Working 
Solution and incubated at 37ºC for 1 hour. Next, the cells were treated with 20 µL of 
selinexor at 1µM or 10 µM concentrations to induce ROS or corresponding volumes of 
DMSO. One set of wells was treated only with 10 µL 1x PBS. Fluorescence changes 
were monitored at 520 nm over varying time periods using the Bio-Tek Synergy 2 
microplate reader and Gen 5 Microplate Data Collection and Analysis Software. If the 
amount of ROS increased, the fluorescence intensity measured also increased.  
 
Statistical Analysis 
 Data were quantified using LiCor Image Studio Lite software and analyzed using 
GraphPad Prism Software. Data were evaluated using a two-tailed, paired student T-test. 
Significance was set at less than 0.05.  
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III. Results 
Selinexor Activates Akt 
Akt is considered a cell survival kinase and it is generally thought that cell death 
can result from decreases in its activity.21  To determine whether selinexor influenced Akt 
activity levels in TNBC cells, Akt activity assays were performed to assess the levels of 
active Akt in BT-549 cells treated with DMSO vehicle or with selinexor.  Relative Akt 
activity levels were determined by evaluating the phosphorylation of the Akt substrate 
GSK-3 by performing Western blot analysis (Figure 3). 
Under vehicle conditions, the levels of Akt activity were low to undetectable.  In 
contrast, the activity levels in cells treated with selinexor were higher than those in 
vehicle-treated cells. In order to obtain a visible signal for the vehicle-treated samples, 
the selinexor-treated samples  band intensities were overe posed. Therefore, over the 
course of the three independent experiments, the data were not quantifiable. However, 
these results suggest that selinexor activates Akt in BT-549 cells.   
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Figure 3: Akt Activity Western Blots Immunoprecipitated Akt was 
incubated with GSK3, a substrate of Akt. Phosphorylated GSK3 is a 
measure of Akt activity. The results show three independent experiments. 
 
Selinexor Does Not Change Akt Protein Levels 
To determine if Akt protein levels changed in response to selinexor, Western 
blotting was performed on vehicle-treated and selinexor-treated cells (Figure 4). Probing 
with a pan-Akt antibody (Figure 4A), the blot revealed no apparent difference in protein 
levels between the two samples. In order to ensure equal protein loading onto the gel, the 
membranes were stripped of primary antibody with 0.1 M HCl and reprobed for actin. 
There appeared to be no difference in the actin levels between the two samples (Figure 
4A). Densitometric analyses of bands revealed a slight increase in the Akt/actin ratio in 
selinexor-treated cells; however, the increase was not statistically significant (p=0.353) 
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(Figure 4B). Overall, these data imply that the selinexor-induced increases in Akt activity 
were not due to elevated Akt protein levels but were reflections of increases in the 
activity of the enzyme already expressed.  
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Figure 4: Total Akt Western Blots 10 µg (Experiments 1 and 2) or 25 µg 
(Experiment 3) of whole cell lysate was subjected to Western blot 
analysis. (A) Blots were probed with a pan Akt antibody. The membranes 
A. 
B. 
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were stripped and reprobed for actin. (B) Densitometric analysis of Akt 
expression. P = 0.3531. Data shown are representative of three 
independent experiments. 
 
Selinexor Does Not Increase Akt T308 Phosphorylation 
Initial activation of Akt occurs via phosphorylation at threonine 308, and for full 
activation, phosphorylation of serine 473 follows. To corroborate the results of the Akt 
activity assays, the levels of phospho-Akt were measured by Western blot using a 
phospho-threonine308-specific Akt antibody (Figure 5).  Probing with this phospho-Akt 
antibody revealed that phosphorylation decreased or had no change upon treatment with 
selinexor (Figure 5A). Densitometric analyses of bands revealed a slight decrease in the 
phospho-Akt/actin ratio in selinexor-treated cells; however, the decrease was not 
statistically significant (p=0.4671) (Figure 5B). Overall, these data imply that the increase 
in Akt activity is not due to phosphorylation at threonine 308.  
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Figure 5: Phospho-Akt Western Blots (A) Blots probed with phospho-
threonine 308-specific Akt antibody. The membrane was stripped and 
reprobed for actin. (B) Densitometric analysis of phosphorylated Akt at 
threonine 308. P = 0.4671. Data shown are representative of 4 independent 
experiments. Overflow of vehicle treated samples into lane 2 was 
observed upon sample loading and was included in the quantification for 
the vehicle sample.  
A. 
B. 
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Selinexor Localizes Akt to the Nucleus 
Since selinexor inhibits nuclear export and Akt localizes to the nucleus in some 
cell lines14, the effects of selinexor on the subcellular localization of Akt in BT-549 cells 
was evaluated. Indirect immunofluorescence was used to visualize the localization of Akt 
in cells under vehicle or treatment conditions (Figure 6). If nuclear export of Akt had 
been inhibited, the antibody would fluoresce red inside the nucleus more brightly in the 
selinexor-treated cells when compared to vehicle-treated cells. Under vehicle conditions, 
Akt was predominantly localized in the nucleus in a few cells and diffusely dispersed 
throughout the cell in the majority of them. However, when treated with selinexor, Akt 
predominantly localized to the nucleus. Based on overall observations, selinexor is able 
to trap Akt in the nucleus by inhibiting XPO1 activity (Figure 6). 
 Cells within each field were counted and categorized as having approximately 
equal staining intensity in the cytoplasm and nucleus or staining predominantly in 
nucleus or cytoplasm (Table 2). In the vehicle treated cells, the majority (45%) of the 
cells appeared to have Akt staining predominantly in the cytoplasm, with 35% of the cells 
having diffuse staining throughout the cell. Of the cells treated with selinexor, 80% 
appeared to have predominantly nuclear staining. These data suggest that selinexor 
causes nuclear accumulation of Akt.  
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Figure 6: Indirect Immunofluorescence of Akt in BT-549 Cells. Akt 
was stained in red using a Cy3 antibody. Nuclei were stained in blue using 
DAPI. Areas of overlap between the Akt protein (red) and the nucleus 
(blue) appear as a purple color. Data shown are representative pictures of 
2 independent experiments.  
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Observation 
Vehicle 
(# of 
cells) 
Vehicle 
(%) 
Selinexor 
(# of cells) 
Selienxor 
(%) 
Equal staining in cytoplasm and 
nucleus 70 35% 14 13% 
Staining predominantly nuclear 29 15% 84 80% 
Staining predominantly cytoplasmic 89 45% 3 3% 
Staining too light to be detected 11 5% 4 4% 
Total Number  199 100% 105 100% 
Table 2: Localization of Intensity of Akt Staining in Vehicle and 
Selinexor Treated Cells Cells were counted and categorized by intensity 
of Cy3TM staining and treatments.   
 
ROS Assays 
Hyperactivation of Akt has been demonstrated to evoke the production of ROS.21 
The extent of activation of Akt in BT-549 cells treated with selinexor could be considered 
hyperactivation. To determine if the cells produce ROS in response to treatment with 
selinexor, ROS assays were performed. Four experiments were conducted using different 
strategies. Cells were plated at three different densities and treated with 2 different 
concentrations of selinexor. Fluorescence measurements were taken at different time 
intervals.  
In experiment one, cells were plated at concentrations of 30,000 cells per well 
(Figure 7A) and 40,000 cells per well (Figure 7B). After one hour, absorbance 
measurements observed for the cells plated at 30,000 cells per well were between 0.08 
and 0.12. The well that received no treatment had a higher reading than three of the 
remaining four treatments. After two hours, the readings were approximately 0.04, with 
some slight differences between treatments. At 21 hours, the measurement again dropped 
 25 
slightly to be approximately 0.03. Twenty-four hours after treatment, two absorbance 
values increased, while three decreased. One of these values became a negative value. In 
the wells that contained 40,000 cells per well, the absorbance values after one hour were 
between 0.05 and 0.1, with the cells that received no treatment being the next to highest 
value. At 2 hours, all absorbance readings were below 0.05 and inconsistent, but the 
10µM vehicle treatment value, which was the highest value at 1 hour, became negative. 
At 21 hours, all values were positive again and around 0.03-0.04. After 24 hours, all 
values were negative, with their absorbance values between -0.13-0.15.  
In experiment two, cells were plated at 60,000 cells per well. At 19 hours and 21 
hours, the highest absorbance values were for those cells that received no treatment. This 
value stayed steady at a value of 0.025 throughout all three timepoints. At 3 hours, the 
10µM selinexor treatment had the highest absorbance value. This value decreased 
slightly at 19 hours and again at 21 hours, but it was still higher than the values for the 
other treatments. In this experiment, the 1µM vehicle treatment yielded a higher 
absorbance value than the 1µM selinexor treatment. However, the 1µM selinexor 
treatment yielded higher absorbance values than the 10 µM vehicle treatment at 3 hours, 
and these values were the same at both 19 and 21 hours.  
The results from experiment three were also inconsistent. At 15 minutes, the 
absorbance values for 1 µM vehicle and 10 µM selinexor were very low, while the values 
for no treatment and 1 µM selinexor were between 0.2 and 0.3. After 30 minutes, the 
absorbance reading for 1 µM selinexor treatment were extremely high, at a value of 
around 0.45, while the other values were approximately 0.1 and lower. After an hour, the 
 26 
value for 1µM selinexor decreased slightly, while the values for no treatment and 1µM 
vehicle treatment increased again.  
Experiment four again shows inconsistent values. After 15 minutes, 1µM 
selinexor treatment yielded a higher absorbance value than any other treatment, but at 
both 30 minutes and 1 hour, 10 µM vehicle treatment yielded the highest absorbance 
values. While most values decreased slightly over time, the 10µM vehicle treatment 
values increased over time. In addition, the 10 µM selinexor treatment values never 
exceeded 0.05 and remained relatively constant.  
When analyzing this data, there were no consistent trends in absorbance values 
when comparing between treatment options. Due to the negative and fluctuating 
absorbance readings, over time, no reliable conclusion could be drawn from the data. In 
spite of different experimental strategies, the data are insufficient to determine if 
selinexor impacts ROS levels in BT-549 cells (Figure 7).   
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Figure 7: ROS Assay Absorbance Readings Cells were treated in a 90-
well plate with 5 different treatments: no treatment, 1 µM DMSO, 1 µM 
selinexor, 10 µM DMSO, and 10 µM selinexor. (A) Cells were plated at 
30,000 cells per well. (B) Cells were plated at 40,000 cells per well. (A-B) 
Absorbance readings were measured at 1 hour, 2 hours, 21 hours, and 24 
hours. (C-E) Cells were plated at 60,000 cells per well. (C) Absorbance 
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readings were measured at 3 hours, 19 hours, and 21 hours. (D-E) 
Absorbance readings were measured at 15 minutes, 30 minutes, and 60 
minutes. V, DMSO; S, Selinexor.  
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IV. Discussion/Conclusion 
Selinexor is currently being used in several clinical trials for cancer and has 
shown anti-cancer effects in combination with other chemotherapies. Clinical trials 
evaluating the use of selinexor in the treatment of triple negative breast cancer are 
limited, but in vitro studies show promising results in its ability to kill triple negative 
breast cancer cells. The mechanism by which this occurs, however, is not understood. 
The goal of this research was to determine the mechanism by which selinexor kills BT-
549 triple negative breast cancer cells.  
Several key observations were made in this research. First, this work has 
demonstrated that selinexor increases Akt activity. This was an unexpected finding. Since 
Akt is generally associated with cell survival, the levels were expected to decrease. In 
contrast, the levels were increased substantially. Hyperactivation of Akt has been 
previously published by Wang et al. when they reported on the effects of targeting Akt 
for potential therapy in diffuse large B-cell lymphoma.22 This hyperactivation may be the 
mechanism utilized by selinexor in order to induce apoptosis in BT-549 cells.  
Second, Akt phosphorylation is dependent on phosphorylation at T308. Therefore, 
it was expected that selinexor would increase the phosphorylation of Akt at this site since 
it induced Akt activity. The results did not indicate an increase in phosphorylation of 
T308, which is required for full activation and downstream phosphorylation of Akt. This 
is confounding as it is generally thought that this is the key to activation of the kinase. 
However, other kinases, such as protein tyrosine kinase 6 (PTK6), have been shown to 
activate Akt.13 PTK6 is not expressed in normal mammary tissue, but is expressed in 
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many breast cancer cells. It phosphorylates Akt at tyrosines 315 and 326 and is localized 
to the nucleus.23  
Third, cells treated with selinexor show increased nuclear localization of Akt. 
This indicates that inhibition of nuclear export in BT-549 cells results in nuclear retention 
of Akt. One important function of nuclear Akt is inhibition of forkhead box protein O1 
(FOXO) transcription factors, which results in decreased expression of FOXO proteins. 
Since FOXO proteins are important for antioxidant production, decreased expression 
could impact the ability of the cells to respond to oxidative stress, such as that caused by 
hyperactivated Akt.  
Lastly, the ROS assays gave inconclusive results, and need to be further 
investigated. Previous experiments in the Odom lab have shown that selinexor kills BT-
549 cells by inducing apoptosis. An increase in ROS levels can cause oxidative stress and 
ROS toxicity to trigger apoptosis. Apoptosis can be induced by many factors, but studies 
have shown that cancer cells with constitutively activated Akt, such as BT-549 cells, are 
more sensitive to ROS-induced apoptosis.16 Given this, it is still possible that levels of 
ROS are affected. Figure 8 demonstrates a model schematic of these events.  
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Figure 8: Proposed Method of Selinexor Induced BT-549 Cell Death 
Selinexor inhibits the function of XPO1. Akt translocates to the nucleus 
and/or mitochondria after being activated at the plasma membrane. In the 
nucleus, Akt inhibits FOXO transcription factors and therefore decreases 
the amount of FOXO and antioxidants produced. At the mitochondria, Akt 
stimulates mitochondrial activity, resulting in an increase in the production 
of ROS.  
 
In conclusion, the data reported here suggests that Akt is being sequestered into 
the nucleus and hyperactivated via an alternative mechanism of activation in BT-549 
cells upon treatment with selinexor. Future experiments to investigate potential 
alternative methods for Akt activation are needed. In addition, ROS assays would need to 
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be repeated and cellular fractionation is needed to support the indirect 
immunofluorescence observations. 
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